Suven Life Sciences spurted to Rs 204.30 this morning, gaining more than 5%, after the company announced that it has secured two products patents in Eurpoe and Israel for treatment of neurodegenerative disorders associated with Neurodegenerative diseases. The stock is now up 2.3% at Rs 199.
Suven said these Patents are valid through 2030 and 2029 respectively. The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder, Huntington’s disease, Major Depressive disorder, Parkinson and Schizophrenia.
With the grant of these new patents, Suven Life Sciences now has a total of 23 granted patents from Europe and 12 granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.